In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tom Gallen

Managing Editor – Europe

Having joined OTC bulletin as a business reporter in 2013, Tom is currently the managing editor and has an intimate knowledge of the global consumer healthcare market, particularly commercial and regulatory issues. He specializes in analyzing the strategies of the world's leading consumer healthcare companies, their business performance, plans and product portfolios.
Set Alert for Articles By Tom Gallen

Latest From Tom Gallen

Pain Relief Most Popular Reason For Using CBD In UK

Pain relief is by far the most popular reason for taking CBD in the UK, a recent survey has revealed. The research by YouGov also finds that a quarter of those who have not tried CBD are tempted to do so. 
Market Intelligence Wellness

Dutch Firms Not Updating Product Info Fast Enough Following Safety Alerts

OTC marketing authorization holders in the Netherlands must respond more quickly to safety alerts issued at EU level which require product information updates, says regulator MEB.
Netherlands Drug Review

Dutch Self-Care Efforts Stumble As Supplement Prescription Costs Rise

Costs of prescriptions for vitamin D supplements in the Netherlands are spiraling with government moves to encourage self-care appearing to have had the opposite effect, according to new research.

Netherlands Dietary Supplements

Boiron Warned Over Use Of Social Media Influencer In French Ad

Using a social media influencer to promote its pro-homeopathy campaign in France without clearly indicating the post was a paid ad has landed Boiron in hot water with local regulators. 
Ad Complaints France

Takeda Offloads Emerging Market OTCs to Acino

Takeda is shedding some unwanted OTC assets in a number of emerging markets as part of its efforts to pay down debt and focus its portfolio following its acquisition of Shire. 
Deals Emerging Markets

Brazil Prepares To Clear Backlog Of 25 Switch Applications

Brazil's drug regulator Anvisa is seeking comments on its backlog of 25 Rx-to-OTC switch applications as it looks to make more prescription products available OTC.
Prescription To Otc Switch South America
See All